1-(6-tert-butylpyridin-2-yl)piperazine | 120145-34-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(6-tert-butylpyridin-2-yl)piperazine
• CAS: 120145-34-8
• 化学式: C₁₃H₂₁N₃
• 分子量: 219.33
• InChiKey: MGIBIXZNOXABAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(6-tert-butylpyridin-2-yl)piperazine 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 9.0h， 生成
  参考文献：
  名称：

  N^ε-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure–Activity Relationships, and Pharmacokinetic Profiling

  摘要：

  Transglutaminase 2 (TGase 2)-catalyzed transamidation represents an important post-translational mechanism for protein modification with implications in physiological and pathophysiological conditions, including fibrotic and neoplastic processes. Consequently, this enzyme is considered a promising target for the diagnosis of and therapy for these diseases. In this study, we report on the synthesis and kinetic characterization of N-acryloyllysine piperazides as irreversible inhibitors of TGase 2. Systematic structural modifications on 54 new compounds were performed with a major focus on fluorine-bearing substituents due to the potential of such compounds to serve as radiotracer candidates for positron emission tomography. The determined inhibitory activities ranged from 100 to 10 000 M-1 s(-1), which resulted in comprehensive structure activity relationships. Structure activity correlations using various substituent parameters accompanied by covalent docking studies provide an advanced understanding of the molecular recognition for this inhibitor class within the active site of TGase 2. Selectivity profiling of selected compounds for other transglutaminases demonstrated an excellent selectivity toward transglutaminase 2. Furthermore, an initial pharmacokinetic profiling of selected inhibitors was performed, including the assessment of potential membrane permeability and liver microsomal stability.

  DOI：

  10.1021/acs.jmedchem.8b00286
• 作为产物：
  描述：

  2-甲基-6-氯吡啶 在 lithium diisopropyl amide 作用下， 以 正丁醇 为溶剂， 反应 69.0h， 生成 1-(6-tert-butylpyridin-2-yl)piperazine
  参考文献：
  名称：

  6-Alkyl-N,N-disubstituted-2-pyridinamines as anticonvulsant agents

  摘要：

  The anticonvulsant effect of a series of 6-alkyl-N,N-disubstituted-2-pyridinamines is described. An investigation was carried out to optimize the anticonvulsant activity and reduce behavioral side effects in this series. Three compounds (7, 8, 10; Table I) were selected from initial screening for a more complete pharmacological evaluation. While each of these compounds was a potent anticonvulsant agent with ED50 values from 5 to 10 mg/kg, the activity was accompanied by significant behavioral side effects including decreased spontaneous locomotion, ataxia, and ptosis.

  DOI：

  10.1021/jm00126a015

文献信息

• Pyrimidine derivatives as kinase inhibitors and their therapeutical applications
  申请人：NantBioScience, Inc.

  公开号：US10766879B2

  公开（公告）日：2020-09-08

  The present invention provides antitumor agents comprising substituted pyrimidine derivatives and pharmaceutically-acceptable formulations thereof, methods for making novel compounds and methods for using the compounds. The compounds and compositions in accordance with the invention have utility in treatment of a variety of diseases and have kinase inhibitory activities.

  本发明提供了由取代的嘧啶衍生物组成的抗肿瘤剂及其药学上可接受的制剂、新型化合物的制造方法和化合物的使用方法。根据本发明的化合物和组合物可用于治疗多种疾病，并具有激酶抑制活性。
• PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS
  申请人：NantBioScience, Inc.

  公开号：US20180155327A1

  公开（公告）日：2018-06-07

  The present invention provides antitumor agents comprising substituted pyrimidine derivatives and pharmaceutically-acceptable formulations thereof, methods for making novel compounds and methods for using the compounds. The compounds and compositions in accordance with the invention have utility in treatment of a variety of diseases and have kinase inhibitory activities.
• <i>N</i>^ε-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure–Activity Relationships, and Pharmacokinetic Profiling
  作者：Robert Wodtke、Christoph Hauser、Gloria Ruiz-Gómez、Elisabeth Jäckel、David Bauer、Martin Lohse、Alan Wong、Johanna Pufe、Friedrich-Alexander Ludwig、Steffen Fischer、Sandra Hauser、Dieter Greif、M. Teresa Pisabarro、Jens Pietzsch、Markus Pietsch、Reik Löser

  DOI：10.1021/acs.jmedchem.8b00286

  日期：2018.5.24

  Transglutaminase 2 (TGase 2)-catalyzed transamidation represents an important post-translational mechanism for protein modification with implications in physiological and pathophysiological conditions, including fibrotic and neoplastic processes. Consequently, this enzyme is considered a promising target for the diagnosis of and therapy for these diseases. In this study, we report on the synthesis and kinetic characterization of N-acryloyllysine piperazides as irreversible inhibitors of TGase 2. Systematic structural modifications on 54 new compounds were performed with a major focus on fluorine-bearing substituents due to the potential of such compounds to serve as radiotracer candidates for positron emission tomography. The determined inhibitory activities ranged from 100 to 10 000 M-1 s(-1), which resulted in comprehensive structure activity relationships. Structure activity correlations using various substituent parameters accompanied by covalent docking studies provide an advanced understanding of the molecular recognition for this inhibitor class within the active site of TGase 2. Selectivity profiling of selected compounds for other transglutaminases demonstrated an excellent selectivity toward transglutaminase 2. Furthermore, an initial pharmacokinetic profiling of selected inhibitors was performed, including the assessment of potential membrane permeability and liver microsomal stability.
• 6-Alkyl-N,N-disubstituted-2-pyridinamines as anticonvulsant agents
  作者：Michael R. Pavia、Charles P. Taylor、Sandra J. Lobbestael

  DOI：10.1021/jm00126a015

  日期：1989.6

  The anticonvulsant effect of a series of 6-alkyl-N,N-disubstituted-2-pyridinamines is described. An investigation was carried out to optimize the anticonvulsant activity and reduce behavioral side effects in this series. Three compounds (7, 8, 10; Table I) were selected from initial screening for a more complete pharmacological evaluation. While each of these compounds was a potent anticonvulsant agent with ED50 values from 5 to 10 mg/kg, the activity was accompanied by significant behavioral side effects including decreased spontaneous locomotion, ataxia, and ptosis.